- ADVANZ PHARMA completes the acquisition of a hospital anti-infective portfolio from Sanofi, including the brands Azactam™, Cefotax™, Claforan™, Oroken™, Rulid™, Suprax™, Wintriaxone™ and Colistimethate Sodique products.
- The acquisition further strengthens ADVANZ PHARMA’s specialty and hospital business in Europe and internationally and builds on its existing anti-infectives expertise.
LONDON, October 03, 2022 - ADVANZ PHARMA Corp. Limited ("ADVANZ PHARMA" or "the Company"), a UK-headquartered global pharmaceutical company with a strategic focus on specialty and hospital pharmaceuticals, today announced the completion of the acquisition of intellectual property, marketing authorisation, and manufacturing and supply agreements of a diverse antibiotics portfolio from Sanofi.
ADVANZ PHARMA acquired this portfolio, made up of eight anti-infectives including Azactam™, Cefotax™, Claforan™, Oroken™, Rulid™, Suprax™, Wintriaxone™ and Colistimethate Sodique products. which are critical in treating a broad range of infections. The key markets are in Europe, Africa, and Asia.
This further reinforces ADVANZ PHARMA’s vision to be a partner of choice for the commercialisation of specialty and hospital pharmaceuticals.
The acquisition of this portfolio nicely builds on ADVANZ’s existing hospital and anti-infectives experience and strengthens its business in selected geographies.
This acquisition demonstrates continued momentum to expand the business via further acquisitions and leverages ADVANZ PHARMA’s capabilities to integrate and commercialise specialty and hospital pharmaceuticals successfully.
The acquisition closed on 30th September 2022.
About ADVANZ PHARMA
ADVANZ PHARMA is a global pharmaceutical company with a strategic focus on specialty and hospital medicines in Europe and Canada. The company has commercial affiliates in Europe, North America and Australia, and a Centre of Excellence in Mumbai, India, as well as an established global network of commercial partners throughout the rest of the world. With an agile and experienced team, including direct sales, marketing, and medical capability across Europe's major markets and Canada, ADVANZ PHARMA is committed to improving lives of patients by providing and enhancing the specialty and hospital medicines they depend on. The company has a broad expertise in several therapeutic areas including hepatology, gastroenterology, critical care, anti-infectives, endocrinology, oncology, and more broadly rare disease medicines, making ADVANZ PHARMA a partner of choice for the commercialisation of specialty and hospital pharmaceuticals.
For media enquiries, please contact:
+44 7776 516979